PMID- 27617315
OWN - NLM
STAT- MEDLINE
DCOM- 20180205
LR  - 20220330
IS  - 2466-054X (Electronic)
IS  - 2466-0493 (Print)
IS  - 2466-0493 (Linking)
VI  - 57
IP  - 5
DP  - 2016 Sep
TI  - Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific 
      antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal 
      digital rectal examination.
PG  - 336-42
LID - 10.4111/icu.2016.57.5.336 [doi]
AB  - PURPOSE: We investigated the extended use of Prostate Health Index (PHI) and 
      percentage of [-2]pro-prostate-specific antigen (%p2PSA) in Chinese men with 
      prostate-specific antigen (PSA) 10-20 ng/mL and normal digital rectal examination 
      (DRE). MATERIALS AND METHODS: All consecutive Chinese men with PSA 10-20 ng/mL 
      and normal DRE who agreed for transrectal ultrasound (TRUS)-guided 10-core 
      prostate biopsy were recruited. Blood samples were taken immediately before 
      TRUS-guided prostate biopsy. The performances of total PSA (tPSA), %free-to-total 
      PSA (%fPSA), %p2PSA, and PHI were compared using logistic regression, receiver 
      operating characteristic, and decision curve analyses (DCA). RESULTS: From 2008 
      to 2015, 312 consecutive Chinese men were included. Among them, 53 out of 312 
      (17.0%) men were diagnosed to have prostate cancer on biopsy. The proportions of 
      men with positive biopsies were 6.7% in PHI<35, 22.8% in PHI 35-55, and 54.5% in 
      PHI>55 (chi-square test, p<0.001). The area under curves (AUC) of the base model 
      including age, tPSA and status of initial/repeated biopsy was 0.64. Adding %p2PSA 
      and PHI to the base model improved the AUC to 0.79 (p<0.001) and 0.78 (p<0.001), 
      respectively, and provided net clinical benefit in DCA. The positive biopsy rates 
      of Gleason 7 or above prostate cancers were 2.2% for PHI<35, 7.9% for PHI 35-55, 
      and 36.4% for PHI>55 (chi-square test, p<0.001). By utilizing the PHI cutoff of 
      35 to men with PSA 10-20 ng/mL and normal DRE, 57.1% (178 of 312) biopsies could 
      be avoided. CONCLUSIONS: Both PHI and %p2PSA performed well in predicting 
      prostate cancer and high grade prostate cancer. The use of PHI and %p2PSA should 
      be extended to Chinese men with PSA 10-20 ng/mL and normal DRE.
FAU - Chiu, Peter Ka-Fung
AU  - Chiu PK
AD  - Department of Surgery, Division of Urology, The Chinese University of Hong Kong, 
      Hong Kong SAR, China.
FAU - Teoh, Jeremy Yuen-Chun
AU  - Teoh JY
AD  - Department of Surgery, Division of Urology, The Chinese University of Hong Kong, 
      Hong Kong SAR, China.
FAU - Lee, Wai-Man
AU  - Lee WM
AD  - Department of Surgery, Division of Urology, The Chinese University of Hong Kong, 
      Hong Kong SAR, China.
FAU - Yee, Chi-Hang
AU  - Yee CH
AD  - Department of Surgery, Division of Urology, The Chinese University of Hong Kong, 
      Hong Kong SAR, China.
FAU - Chan, Eddie Shu-Yin
AU  - Chan ES
AD  - Department of Surgery, Division of Urology, The Chinese University of Hong Kong, 
      Hong Kong SAR, China.
FAU - Hou, See-Ming
AU  - Hou SM
AD  - Department of Surgery, Division of Urology, The Chinese University of Hong Kong, 
      Hong Kong SAR, China.
FAU - Ng, Chi-Fai
AU  - Ng CF
AD  - Department of Surgery, Division of Urology, The Chinese University of Hong Kong, 
      Hong Kong SAR, China.; Department of Surgery, SH Ho Urology Centre, The Chinese 
      University of Hong Kong, Hong Kong SAR, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20160831
PL  - Korea (South)
TA  - Investig Clin Urol
JT  - Investigative and clinical urology
JID - 101674989
RN  - 0 ((-2)pro-prostate-specific antigen, human)
RN  - 0 (Protein Precursors)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy, Large-Core Needle/methods
MH  - *Digital Rectal Examination
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Prostate-Specific Antigen/*blood
MH  - Prostatic Neoplasms/*diagnosis/pathology
MH  - Protein Precursors/blood
MH  - ROC Curve
MH  - Ultrasonography, Interventional/methods
PMC - PMC5017555
OTO - NOTNLM
OT  - Biomarkers
OT  - Biopsy
OT  - Prostate
OT  - Prostate neoplasms
OT  - Prostate-specific antigen
COIS- The authors have nothing to disclose.
EDAT- 2016/09/13 06:00
MHDA- 2018/02/06 06:00
PMCR- 2016/09/01
CRDT- 2016/09/13 06:00
PHST- 2016/06/03 00:00 [received]
PHST- 2016/07/21 00:00 [accepted]
PHST- 2016/09/13 06:00 [entrez]
PHST- 2016/09/13 06:00 [pubmed]
PHST- 2018/02/06 06:00 [medline]
PHST- 2016/09/01 00:00 [pmc-release]
AID - 10.4111/icu.2016.57.5.336 [doi]
PST - ppublish
SO  - Investig Clin Urol. 2016 Sep;57(5):336-42. doi: 10.4111/icu.2016.57.5.336. Epub 
      2016 Aug 31.